EKF Diagnostics Holdings plc (LON:EKF - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 25.91 ($0.34) and traded as low as GBX 20.10 ($0.26). EKF Diagnostics shares last traded at GBX 20.76 ($0.27), with a volume of 863,267 shares traded.
EKF Diagnostics Stock Performance
The company has a current ratio of 4.60, a quick ratio of 1.77 and a debt-to-equity ratio of 0.34. The company has a 50-day moving average price of GBX 23.04 and a two-hundred day moving average price of GBX 25.78. The stock has a market capitalization of £97.34 million, a P/E ratio of 20.38 and a beta of 0.57.
EKF Diagnostics (LON:EKF - Get Free Report) last posted its quarterly earnings results on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) EPS for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. On average, equities analysts forecast that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current year.
Insiders Place Their Bets
In other EKF Diagnostics news, insider Gavin T. Jones acquired 50,000 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were purchased at an average cost of GBX 22 ($0.28) per share, with a total value of £11,000 ($14,237.64). Corporate insiders own 5.24% of the company's stock.
About EKF Diagnostics
(
Get Free Report)
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Recommended Stories
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
